<DOC>
	<DOC>NCT01915134</DOC>
	<brief_summary>The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).</brief_summary>
	<brief_title>Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse reaction of recombinant human endostatin (endostar) combined with chemotherapy to the metastatic nasopharyngeal carcinoma (NPC).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>metastatic nasopharyngeal carcinoma 6 months after first treatment,never receive any anticancer treatment except local radiotherapy to the bone metastasis，at least one measurable metastatic lesions，ECOG PS 01，Electrocardiogram (ecg) no special abnormal，comply with the test requirements, cooperate with regular followup. To give local treatment,clinical severe infection(&gt;grade 2),with the central nervous system metastases,ECOG PS≥2,patients with pregnancy or breastfeeding,has a history of peripheral nerve disease,concomitant with other serious diseases,ever or concomitant with other serious diseases except for Cervical carcinoma in situ,cure of basal cell carcinoma,bladder surface tumor,any cancer 3 years after curation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>Recombinant Human Endostatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>gemcitabine and cisplatin</keyword>
</DOC>